Back to News
Market Impact: 0.2
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
Source: GlobeNewswire
Healthcare & Biotech
The Dutch Cardiovascular Investigator Network (WCN) leads European enrollment in a Phase 3 study evaluating etripamil nasal spray for atrial fibrillation with rapid ventricular response (AFib-RVR). The headline provides no enrollment totals, trial results, or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
- Alignment Healthcare Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Alignment Healthcare (ALHC)